πŸ‡ΊπŸ‡Έ FDA
Patent

US 10828315

Targeted therapeutics

granted A61KA61K31/165A61K31/167

Quick answer

US patent 10828315 (Targeted therapeutics) held by Madrigal Pharmaceuticals, Inc. expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Madrigal Pharmaceuticals, Inc.
Grant date
Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/165, A61K31/167, A61K31/416, A61K31/4184